Resection margin

IO Biotech Announces Third Quarter Results for 2022

Retrieved on: 
Wednesday, November 9, 2022
MSD, GLOBE, Meeting, IO, Head, Forward-looking statement, Poster, Nivolumab, Melanoma, Annual general meeting, Nasdaq, Immunotherapy, Income, Adjuvant, CR, Merck, IDO, ARG1, Hand, Securities Act of 1933, Large-cell lung carcinoma, MOS, Merck & Co., PD-L1, Safety, PD-1, Resection margin, Securities Exchange Act of 1934, SITC, Company, Neoplasm, Pembrolizumab, Research, Clinical trial, Chemistry, Neck, Drug Quality and Security Act, NEW, Multi, Society, Trial of the century, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient

See the following press release for more information, IO Biotech ApS - IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting .

Key Points: 
  • See the following press release for more information, IO Biotech ApS - IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting .
  • Ms. Sullivan brings 30 years of experience building biotech companies to IO Biotech.
  • See the following press release for more information, IO Biotech ApS - IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors .
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.

Dune Medical Devices, Pioneer in RF Spectroscopy, Continues to Lead with Clinical Data Supporting the Only FDA Approved Device for Identifying Positive Margins During Breast Conservation Surgery

Retrieved on: 
Tuesday, February 12, 2019
Women, Surgery, Health, Clinical trials, Medical devices, Oncology, FDA, Consumer, Medicine, RTT, Clinical medicine, Surgical oncology, Medical specialties, Breast surgery, Breast cancer, Cancer, Resection margin, Lumpectomy

Reducing re-excision rates due to positive margins is a significant focus of the breast cancer medical community.

Key Points: 
  • Reducing re-excision rates due to positive margins is a significant focus of the breast cancer medical community.
  • Recent SSO-ASTRO guidelines defining positive margins for early-stage invasive breast cancer as No Tumor on Ink have not shown a significant effect on re-excision rates.
  • The PAS results will continue to strengthen the compendium of data already available on the use of MarginProbe for identifying positive margins intraoperatively.
  • By reducing avoidable surgeries, the use of MarginProbe is offering a significant improvement in surgical care for breast cancer patients.